AstraZeneca’s cancer drug shows no improvement in overall survival rates
Advanced breast cancer drug trial disappointsDrug unlikely to receive US approvalSeveral trials could yet revive hopesAnglo-Swedish pharmaceutical giant AstraZeneca (AZN) was on the back foot on Monday after reporting disappointing...
23 September 2024